Predictors of opportunistic infections among people living with HIV: a prospective cohort study from a tertiary care setting in India

印度一家三级医疗机构开展的前瞻性队列研究:艾滋病毒感染者机会性感染的预测因素

阅读:1

Abstract

Opportunistic infections (OIs) remain a leading cause of morbidity and mortality among people living with HIV (PLHIV). Early identification of high-risk individuals is vital to guide the preventive measures and the efficient use of healthcare resources. We conducted a prospective longitudinal cohort study involving 223 PLHIV at a tertiary care center in Western India. Baseline demographic, clinical, and laboratory data were collected, including CD4 count, nutritional status, serum albumin, and ART (antiretroviral therapy) history. Patients were followed for the development of OIs. Logistic regression was used to identify independent predictors of OIs. Kaplan-Meier curves were used to assess OI-free survival across different groups. Out of 223 patients, 97 (43.5%) developed at least one OI. The maximum duration of follow-up was 36 months for OI development. Tuberculosis (41.2%), candidiasis (16.5%), and NTM (Non-tuberculous mycobacteria) infections (11.3%) were the most common OIs. On multivariable analysis, low body mass index (BMI < 18.5 kg/m(2); OR 2.5, 95% CI 1.1-4.2, p = 0.037), hypoalbuminemia (OR 2.3, 95% CI 1.2-3.5, p = 0.011), and CD4 count < 250 cells/µL (OR 2.1, 95% CI 1.3-4.2, p = 0.043) were identified as independent predictors of OIs. Kaplan-Meier analysis showed significantly reduced OI-free survival among patients with albumin < 2.5 g/dL (adjusted HR 1.8; 95% CI 1.1-2.9; p = 0.017) and BMI < 18.5 kg/m(2) (adjusted HR 2.1; 95% CI 1.3-3.2; p = 0.001). Low BMI, hypoalbuminemia, and CD4 count < 250 cells/µL are independent predictors of OIs in PLHIV. Integrating these markers can mitigate the OI-related adverse outcomes, particularly in low-resource healthcare settings.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。